Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.01) by 38.61 percent. This is a 88.57 percent increase over losses of $(12.25) per share from the same period last year.